KPV (lysine-proline-valine) is a tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH), studied for anti-inflammatory effects in the gut. Most of the data sits in preclinical work on inflammatory bowel disease and colitis models, with limited human evidence.
On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention to recommend adding KPV to the Section 503A bulks list. The vote matched the identical BPC-157 tally from earlier in the same session and overrode the June 29-30 FDA career-staff briefing documents that recommended against inclusion, citing thin human clinical trial evidence and 503A historical use questions. The recommendation is advisory; FDA rulemaking to actually add KPV to the bulks list takes approximately 6-18 months.
KPV has been marketed through wellness clinics and online vendors, often paired with BPC-157 in 'gut healing' protocols. State medical boards have included it in enforcement actions against peptide clinics. Human clinical evidence remains thin. Stories here cover the July 2026 PCAC outcome, any registered human trials, and enforcement around its sale. See [[pcac]] and [[peptide-compounding]] for adjacent threads.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
Scientific American published a comprehensive April 18 feature examining the self-injection wellness peptide movement, focusing on BPC-157, TB-500, GHK-Cu, KPV, and ipamorelin. The piece notes that only three small pilot studies have looked at BPC-157 in humans, that most evidence is from rodent models, and that consumers are ordering the compounds from overseas — usually from China — while the FDA prepares to review the category at its July advisory panel.
PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.